#BEGIN_DRUGCARD DB00140

# AHFS_Codes:
Not Available

# ATC_Codes:
A11HA04

# Absorption:
Vitamin B2 is readily absorbed from the upper gastrointestinal tract.

# Biotransformation:
Hepatic.

# Brand_Mixtures:
Not Available

# Brand_Names:
Aqua-Flave
Beflavin
Beflavine
Bisulase
Dermadram
Fiboflavin
Flavaxin
Flavin Bb
Flaxain
HSDB 817
Hyflavin
Hyre
Lactobene
Ovoflavin
Ribipca
Ribocrisina
Riboderm
Ribosyn
Ribotone
Ribovel
Vitaflavine
Vitasan B2

# CAS_Registry_Number:
83-88-5

# ChEBI_ID:
17015

# Chemical_Formula:
C17H20N4O6

# Chemical_IUPAC_Name:
7,8-dimethyl-10-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-2H,3H,4H,10H-benzo[g]pteridine-2,4-dione

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2239929

# Description:
Nutritional factor found in milk, eggs, malted barley, liver, kidney, heart, and leafy vegetables. The richest natural source is yeast. It occurs in the free form only in the retina of the eye, in whey, and in urine; its principal forms in tissues and cells are as flavin mononucleotide and flavin-adenine dinucleotide. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Photosensitizing Agents
Radiation-Sensitizing Agents
Vitamin B Complex
Vitamins (Vitamin B Complex)

# Drug_Interactions:
Not Available

# Drug_Reference:
8604671	Zempleni J, Galloway JR, McCormick DB: Pharmacokinetics of orally and intravenously administered riboflavin in healthy humans. Am J Clin Nutr. 1996 Jan;63(1):54-66.

# Drug_Type:
Approved
Nutraceutical
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-1.46

# Experimental_Logs:
-3.68

# Experimental_Water_Solubility:
84.7 mg/L (at 25 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Riboflavin

# HET_ID:
Not Available

# Half_Life:
66-84 minutes

# InChI_Identifier:
InChI=1S/C17H20N4O6/c1-7-3-9-10(4-8(7)2)21(5-11(23)14(25)12(24)6-22)15-13(18-9)16(26)20-17(27)19-15/h3-4,11-12,14,22-25H,5-6H2,1-2H3,(H,20,26,27)/t11-,12+,14-/m0/s1

# InChI_Key:
InChIKey=AUNGANRZJHBGPY-SCRDCRAPSA-N

# Indication:
For the treatment of ariboflavinosis (vitamin B2 deficiency).

# KEGG_Compound_ID:
C00255

# KEGG_Drug_ID:
D00050

# LIMS_Drug_ID:
140

# Mechanism_Of_Action:
Binds to riboflavin hydrogenase, riboflavin kinase, and riboflavin synthase. Riboflavin is the precursor of flavin mononucleotide (FMN, riboflavin monophosphate) and flavin adenine dinucleotide (FAD). The antioxidant activity of riboflavin is principally derived from its role as a precursor of FAD and the role of this cofactor in the production of the antioxidant reduced glutathione. Reduced glutathione is the cofactor of the selenium-containing glutathione peroxidases among other things. The glutathione peroxidases are major antioxidant enzymes. Reduced glutathione is generated by the FAD-containing enzyme glutathione reductase.

# Melting_Point:
280 dec °C

# Molecular_Weight_Avg:
376.3639

# Molecular_Weight_Mono:
376.138284392

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
1HE5

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/rib_0263.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA451242

# Pharmacology:
Riboflavin or vitamin B2 is an easily absorbed, water-soluble micronutrient with a key role in maintaining human health. Like the other B vitamins, it supports energy production by aiding in the metabolising of fats, carbohydrates, and proteins. Vitamin B2 is also required for red blood cell formation and respiration, antibody production, and for regulating human growth and reproduction. It is essential for healthy skin, nails, hair growth and general good health, including regulating thyroid activity. Riboflavin also helps in the prevention or treatment of many types of eye disorders, including some cases of cataracts.

# Predicted_LogP_Hydrophobicity:
-1.1

# Predicted_LogS:
-2.8

# Predicted_Water_Solubility:
6.57e-01 g/l

# Primary_Accession_No:
DB00140

# Protein_Binding:
60%

# PubChem_Compound_ID:
493570

# PubChem_Substance_ID:
46507342

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD00626
EXPT02760
NUTR00010

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC1=C(C)C=C2N(C[C@H](O)[C@H](O)[C@H](O)CO)C3=NC(=O)NC(=O)C3=NC2=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Lactoflavin
Lactoflavine
Riboflavina [INN-Spanish]
Riboflavine [INN-French]
Riboflavinum [INN-Latin]
Russupteridine Yellow III
Vitamin B2
Vitamin Bi
Vitamin G

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:19:07 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Riboflavin

# pKa_Isoelectric_Point:
10.2

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
MTHFR

# Phase_1_Metabolizing_Enzyme_1_ID:
3917

# Phase_1_Metabolizing_Enzyme_1_Name:
Methylenetetrahydrofolate reductase

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Methylenetetrahydrofolate reductase
MVNEARGNSSLNPCLEGSASSGSESSKDSSRCSTPGLDPERHERLREKMRRRLESGDKWF
SLEFFPPRTAEGAVNLISRFDRMAAGGPLYIDVTWHPAGDPGSDKETSSMMIASTAVNYC
GLETILHMTCCRQRLEEITGHLHKAKQLGLKNIMALRGDPIGDQWEEEEGGFNYAVDLVK
HIRSEFGDYFDICVAGYPKGHPEAGSFEADLKHLKEKVSAGADFIITQLFFEADTFFRFV
KACTDMGITCPIVPGIFPIQGYHSLRQLVKLSKLEVPQEIKDVIEPIKDNDAAIRNYGIE
LAVSLCQELLASGLVPGLHFYTLNREMATTEVLKRLGMWTEDPRRPLPWALSAHPKRREE
DVRPIFWASRPKSYIYRTQEWDEFPNGRWGNSSSPAFGELKDYYLFYLKSKSPKEELLKM
WGEELTSEESVFEVFVLYLSGEPNRNGHKVTCLPWNDEPLAAETSLLKEELLRVNRQGIL
TINSQPNINGKPSSDPIVGWGPSGGYVFQKAYLEFFTSRETAEALLQVLKKYELRVNYHL
VNVKGENITNAPELQPNAVTWGIFPGREIIQPTVVDPVSFMFWKDEAFALWIERWGKLYE
EESPSRTIIQYIHDNYFLVNLVDNDFPLDNCLWQVVEDTLELLNRPTQNARETEAP

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P42898

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
MAOA

# Phase_1_Metabolizing_Enzyme_2_ID:
3941

# Phase_1_Metabolizing_Enzyme_2_Name:
Amine oxidase [flavin-containing] A

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Amine oxidase [flavin-containing] A
MENQEKASIAGHMFDVVVIGGGISGLSAAKLLTEYGVSVLVLEARDRVGGRTYTIRNEHV
DYVDVGGAYVGPTQNRILRLSKELGIETYKVNVSERLVQYVKGKTYPFRGAFPPVWNPIA
YLDYNNLWRTIDNMGKEIPTDAPWEAQHADKWDKMTMKELIDKICWTKTARRFAYLFVNI
NVTSEPHEVSALWFLWYVKQCGGTTRIFSVTNGGQERKFVGGSGQVSERIMDLLGDQVKL
NHPVTHVDQSSDNIIIETLNHEHYECKYVINAIPPTLTAKIHFRPELPAERNQLIQRLPM
GAVIKCMMYYKEAFWKKKDYCGCMIIEDEDAPISITLDDTKPDGSLPAIMGFILARKADR
LAKLHKEIRKKKICELYAKVLGSQEALHPVHYEEKNWCEEQYSGGCYTAYFPPGIMTQYG
RVIRQPVGRIFFAGTETATKWSGYMEGAVEAGERAAREVLNGLGKVTEKDIWVQEPESKD
VPAVEITHTFWERNLPSVSGLLKIIGFSTSVTALGFVLYKYKLLPRS

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P21397

# Drug_Target_1_Cellular_Location:
Cytoplasm

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
15668000	Solovieva IM, Kreneva RA, Errais Lopes L, Perumov DA: The riboflavin kinase encoding gene ribR of Bacillus subtilis is a part of a 10 kb operon, which is negatively regulated by the yrzC gene product. FEMS Microbiol Lett. 2005 Feb 1;243(1):51-8.
16081269	Werner R, Manthey KC, Griffin JB, Zempleni J: HepG2 cells develop signs of riboflavin deficiency within 4 days of culture in riboflavin-deficient medium. J Nutr Biochem. 2005 Oct;16(10):617-24.
16183635	Sandoval FJ, Roje S: An FMN hydrolase is fused to a riboflavin kinase homolog in plants. J Biol Chem. 2005 Nov 18;280(46):38337-45. Epub 2005 Sep 23.
16962092	Bertollo CM, Oliveira AC, Rocha LT, Costa KA, Nascimento EB Jr, Coelho MM: Characterization of the antinociceptive and anti-inflammatory activities of riboflavin in different experimental models. Eur J Pharmacol. 2006 Oct 10;547(1-3):184-91. Epub 2006 Jul 26.
17290783	Ishchuk OP, Iatsyshyn VIu, Dmytruk KV, Voronovs'kyi AIa, Fedorovych DV, Sybirnyi AA: [Construction of the flavinogenic yeast Candida famata strains with high riboflavin kinase activity using gene engineering] Ukr Biokhim Zh. 2006 Sep-Oct;78(5):63-9.
21308351	Hirano G, Izumi H, Yasuniwa Y, Shimajiri S, Ke-Yong W, Sasagiri Y, Kusaba H, Matsumoto K, Hasegawa T, Akimoto M, Akashi K, Kohno K: Involvement of riboflavin kinase expression in cellular sensitivity against cisplatin. Int J Oncol. 2011 Apr;38(4):893-902.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
RFK

# Drug_Target_1_GenBank_ID_Gene:
AK002011

# Drug_Target_1_GenBank_ID_Protein:
7023634

# Drug_Target_1_GeneCard_ID:
RFK

# Drug_Target_1_Gene_Name:
RFK

# Drug_Target_1_Gene_Sequence:
>489 bp
ATGCCCCGAGCGGACTGCATTATGAGGCACCTGCCTTACTTCTGCCGGGGTCAAGTGGTG
CGGGGCTTCGGCCGCGGCTCCAAGCAGCTGGGCATCCCCACAGCTAATTTTCCTGAGCAA
GTGGTAGATAATCTTCCAGCTGATATATCCACTGGTATTTACTATGGTTGGGCCAGTGTT
GGAAGTGGAGATGTCCATAAGATGGTGGTGAGCATAGGATGGAACCCATATTACAAGAAT
ACGAAGAAGTCTATGGAAACACATATCATGCATACCTTCAAAGAGGACTTCTATGGGGAA
ATCCTCAGTGTGGCCATTGTTGGCTACCTGAGACCAGAAAAGAACTTTGATTCTTTAGAG
TCACTTATTTCAGCAATTCAAGGTGATATTGAAGAAGCTAAGAAACGACTAGAGTTACCA
GAACATTTGAAAATCAAAGAAGACAATTTCTTCCAGGTTTCTAAAAGCAAAATAATGAAT
GGCCACTGA

# Drug_Target_1_General_Function:
Coenzyme transport and metabolism

# Drug_Target_1_General_References:
12623014	Karthikeyan S, Zhou Q, Mseeh F, Grishin NV, Osterman AL, Zhang H: Crystal structure of human riboflavin kinase reveals a beta barrel fold and a novel active site arch. Structure. 2003 Mar;11(3):265-73.

# Drug_Target_1_HGNC_ID:
HGNC:30324

# Drug_Target_1_HPRD_ID:
17969

# Drug_Target_1_ID:
408

# Drug_Target_1_Locus:
9q21.13

# Drug_Target_1_Molecular_Weight:
18410

# Drug_Target_1_Name:
Riboflavin kinase

# Drug_Target_1_Number_of_Residues:
162

# Drug_Target_1_PDB_ID:
1Q9S

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF01687	Flavokinase

# Drug_Target_1_Protein_Sequence:
>Riboflavin kinase
MPRADCIMRHLPYFCRGQVVRGFGRGSKQLGIPTANFPEQVVDNLPADISTGIYYGWASV
GSGDVHKMVVSIGWNPYYKNTKKSMETHIMHTFKEDFYGEILNVAIVGYLRPEKNFDSLE
SLISAIQGDIEEAKKRLELPEHLKIKEDNFFQVSKSKIMNGH

# Drug_Target_1_Reaction:
ATP + riboflavin = ADP + FMN

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Catalyzes the phosphorylation of riboflavin (vitamin B2) to form flavin-mononucleotide (FMN)

# Drug_Target_1_SwissProt_ID:
Q969G6

# Drug_Target_1_SwissProt_Name:
RIFK_HUMAN

# Drug_Target_1_Synonyms:
ATP:riboflavin 5'-phosphotransferase
EC 2.7.1.26
Flavokinase

# Drug_Target_1_Theoretical_pI:
8.22

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
20143812	Kim RR, Illarionov B, Joshi M, Cushman M, Lee CY, Eisenreich W, Fischer M, Bacher A: Mechanistic insights on riboflavin synthase inspired by selective binding of the 6,7-dimethyl-8-ribityllumazine exomethylene anion. J Am Chem Soc. 2010 Mar 10;132(9):2983-90.
20148904	Long Q, Ji L, Wang H, Xie J: Riboflavin biosynthetic and regulatory factors as potential novel anti-infective drug targets. Chem Biol Drug Des. 2010 Apr;75(4):339-47. Epub 2010 Feb 8.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
X69109

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
ribE

# Drug_Target_2_Gene_Sequence:
>642 bp
ATGTTTACGGGGATTGTACAGGGCACCGCAAAACTGGTGTCGATTGACGAGAAACCAAAT
TTTCGTACGCATGTGGTGGAGTTACCCGACCACATGCTGGACGGCCTGGAAACCGGTGCT
TCCGTGGCGCATAACGGTTGCTGCCTGACCGTGACGGAAATTAACGGCAACCATGTCAGT
TTTGACCTGATGAAAGAAACGTTACGCATTACCAATCTTGGCGATTTAAAAGTGGGGGAT
TGGGTAAACGTTGAGCGTGCGGCGAAATTCAGTGATGAAATTGGCGGACACTTAATGTCA
GGTCATATTATGACCACTGCTGAAGTGGCGAAAATATTAACCTCAGAAAATAATCGCCAG
ATCTGGTTTAAAGTCCAGGATAGTCAGTTGATGAAATATATTCTGTACAAAGGATTTATT
GGCATCGACGGTATTAGCCTGACCGTCGGCGAAGTCACGCCAACGCGTTTTTGCGTCCAT
TTAATTCCGGAAACACTGGAACGCACGACTCTTGGGAAGAAAAAACTTGGCGCACGCGTC
AACATTGAAATCGATCCACAAACTCAGGCAGTGGTAGATACGGTAGAACGTGTGCTGGCG
GCACGAGAAAATGCCATGAATCAACCAGGCACAGAAGCCTGA

# Drug_Target_2_General_Function:
Coenzyme transport and metabolism

# Drug_Target_2_General_References:
11377200	Liao DI, Wawrzak Z, Calabrese JC, Viitanen PV, Jordan DB: Crystal structure of riboflavin synthase. Structure. 2001 May 9;9(5):399-408.
9022701	Eberhardt S, Richter G, Gimbel W, Werner T, Bacher A: Cloning, sequencing, mapping and hyperexpression of the ribC gene coding for riboflavin synthase of Escherichia coli. Eur J Biochem. 1996 Dec 15;242(3):712-9.
9023191	Hensel M, Shea JE, Baumler AJ, Gleeson C, Blattner F, Holden DW: Analysis of the boundaries of Salmonella pathogenicity island 2 and the corresponding chromosomal region of Escherichia coli K-12. J Bacteriol. 1997 Feb;179(4):1105-11.
9097039	Aiba H, Baba T, Hayashi K, Inada T, Isono K, Itoh T, Kasai H, Kashimoto K, Kimura S, Kitakawa M, Kitagawa M, Makino K, Miki T, Mizobuchi K, Mori H, Mori T, Motomura K, Nakade S, Nakamura Y, Nashimoto H, Nishio Y, Oshima T, Saito N, Sampei G, Horiuchi T, et al.: A 570-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 28.0-40.1 min region on the linkage map. DNA Res. 1996 Dec 31;3(6):363-77.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
5698

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
23445

# Drug_Target_2_Name:
Riboflavin synthase alpha chain

# Drug_Target_2_Number_of_Residues:
213

# Drug_Target_2_PDB_ID:
1I8D

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00677	Lum_binding

# Drug_Target_2_Protein_Sequence:
>Riboflavin synthase alpha chain
MFTGIVQGTAKLVSIDEKPNFRTHVVELPDHMLDGLETGASVAHNGCCLTVTEINGNHVS
FDLMKETLRITNLGDLKVGDWVNVERAAKFSDEIGGHLMSGHIMTTAEVAKILTSENNRQ
IWFKVQDSQLMKYILYKGFIGIDGISLTVGEVTPTRFCVHLIPETLERTTLGKKKLGARV
NIEIDPQTQAVVDTVERVLAARENAMNQPGTEA

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Riboflavin synthase is a bifunctional enzyme complex catalyzing the formation of riboflavin from 5-amino-6-(1'-D)- ribityl-amino-2,4(1H,3H)-pyrimidinedione and L-3,4-dihydrohy-2- butanone-4-phosphate via 6,7-dimethyl-8-lumazine. The alpha subunit catalyzes the dismutation of 6,7-dimethyl-8-lumazine to riboflavin and 5-amino-6-(1'-D)-ribityl-amino-2,4(1H,3H)- pyrimidinedione

# Drug_Target_2_SwissProt_ID:
P0AFU8

# Drug_Target_2_SwissProt_Name:
RISA_ECOLI

# Drug_Target_2_Synonyms:
EC 2.5.1.9

# Drug_Target_2_Theoretical_pI:
5.88

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Cytoplasm (Potential)

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
14769034	Russell TR, Demeler B, Tu SC: Kinetic mechanism and quaternary structure of Aminobacter aminovorans NADH:flavin oxidoreductase: an unusual flavin reductase with bound flavin. Biochemistry. 2004 Feb 17;43(6):1580-90.
16544142	van Pee KH, Patallo EP: Flavin-dependent halogenases involved in secondary metabolism in bacteria. Appl Microbiol Biotechnol. 2006 May;70(6):631-41. Epub 2006 Mar 17.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
BLVRB

# Drug_Target_3_GenBank_ID_Gene:
D26308

# Drug_Target_3_GenBank_ID_Protein:
1384068

# Drug_Target_3_GeneCard_ID:
BLVRB

# Drug_Target_3_Gene_Name:
BLVRB

# Drug_Target_3_Gene_Sequence:
>621 bp
ATGGCCGTCAAGAAGATCGCGATCTTCGGCGCCACTGGCCAGACCGGGCTCACCACCCTG
GCGCAGGCGGTGCAAGCAGGTTACGAAGTGACAGTGCTGGTGCGGGACTCCTCCAGGCTG
CCATCAGAGGGGCCCCGGCCGGCCCACGTGGTAGTGGGAGATGTTCTGCAGGCAGCCGAT
GTGGACAAGACCGTGGCTGGGCAGGACGCTGTCATCGTGCTGCTGGGCACCCGCAATGAC
CTCAGTCCCACGACAGTGATGTCCGAGGGCGCCCGGAACATTGTGGCAGCCATGAAGGCT
CATGGTGTGGACAAGGTCGTGGCCTGCACCTCGGCTTTCCTGCTCTGGGACCCTACCAAG
GTGCCCCCACGACTGCAGGCTGTGACTGATGACCACATCCGGATGCACAAGGTGCTGCGG
GAATCAGGCCTGAAGTACGTGGCTGTGATGCCGCCACACATAGGAGACCAGCCACTAACT
GGGGCGTACACAGTGACCCTGGATGGACGAGGGCCCTCAAGGGTCATCTCCAAACATGAC
CTGGGCCATTTCATGCTGCGCTGCCTCACCACCGATGAGTACGACGGACACAGCACCTAC
CCCTCCCACCAGTACCAGTAG

# Drug_Target_3_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_3_General_References:
11224564	Pereira PJ, Macedo-Ribeiro S, Parraga A, Perez-Luque R, Cunningham O, Darcy K, Mantle TJ, Coll M: Structure of human biliverdin IXbeta reductase, an early fetal bilirubin IXbeta producing enzyme. Nat Struct Biol. 2001 Mar;8(3):215-20.
1286669	Hochstrasser DF, Frutiger S, Paquet N, Bairoch A, Ravier F, Pasquali C, Sanchez JC, Tissot JD, Bjellqvist B, Vargas R, et al.: Human liver protein map: a reference database established by microsequencing and gel comparison. Electrophoresis. 1992 Dec;13(12):992-1001.
7929092	Yamaguchi T, Komoda Y, Nakajima H: Biliverdin-IX alpha reductase and biliverdin-IX beta reductase from human liver. Purification and characterization. J Biol Chem. 1994 Sep 30;269(39):24343-8.
8117274	Chikuba K, Yubisui T, Shirabe K, Takeshita M: Cloning and nucleotide sequence of a cDNA of the human erythrocyte NADPH-flavin reductase. Biochem Biophys Res Commun. 1994 Feb 15;198(3):1170-6.
8280170	Yamaguchi T, Komuro A, Nakano Y, Tomita M, Nakajima H: Complete amino acid sequence of biliverdin-IX beta reductase from human liver. Biochem Biophys Res Commun. 1993 Dec 30;197(3):1518-23.
8313871	Golaz O, Hughes GJ, Frutiger S, Paquet N, Bairoch A, Pasquali C, Sanchez JC, Tissot JD, Appel RD, Walzer C, et al.: Plasma and red blood cell protein maps: update 1993. Electrophoresis. 1993 Nov;14(11):1223-31.
8687377	Shalloe F, Elliott G, Ennis O, Mantle TJ: Evidence that biliverdin-IX beta reductase and flavin reductase are identical. Biochem J. 1996 Jun 1;316 ( Pt 2):385-7.
8799475	Komuro A, Tobe T, Hashimoto K, Nakano Y, Yamaguchi T, Nakajima H, Tomita M: Molecular cloning and expression of human liver biliverdin-IX beta reductase. Biol Pharm Bull. 1996 Jun;19(6):796-804.

# Drug_Target_3_HGNC_ID:
HGNC:1063

# Drug_Target_3_HPRD_ID:
02967

# Drug_Target_3_ID:
654

# Drug_Target_3_Locus:
19q13.1-q13.2

# Drug_Target_3_Molecular_Weight:
21988

# Drug_Target_3_Name:
Flavin reductase

# Drug_Target_3_Number_of_Residues:
205

# Drug_Target_3_PDB_ID:
1HE5

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF01370	Epimerase

# Drug_Target_3_Protein_Sequence:
>Flavin reductase
AVKKIAIFGATGQTGLTTLAQAVQAGYEVTVLVRDSSRLPSEGPRPAHVVVGDVLQAADV
DKTVAGQDAVIVLLGTRNDLSPTTVMSEGARNIVAAMKAHGVDKVVACTSAFLLWDPTKV
PPRLQAVTDDHIRMHKVLRESGLKYVAVMPPHIGDQPLTGAYTVTLDGRGPSRVISKHDL
GHFMLRCLTTDEYDGHSTYPSHQYQ

# Drug_Target_3_Reaction:
bilirubin + NAD(P)+ = biliverdin + NAD(P)H + H+

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Catalyzes electron transfer from reduced pyridine nucleotides to flavins as well as methylene blue, pyrroloquinoline quinone, riboflavin, or methemoglobin. Possible role in protecting cells from oxidative damage or in regulating iron metabolism. In the liver, converts biliverdin to bilirubin

# Drug_Target_3_SwissProt_ID:
P30043

# Drug_Target_3_SwissProt_Name:
BLVRB_HUMAN

# Drug_Target_3_Synonyms:
BVR-B
Biliverdin reductase B
Biliverdin-IX beta-reductase
EC 1.3.1.24
EC 1.5.1.30
FLR
FR
GHBP
Green heme-binding protein
NADPH-dependent diaphorase
NADPH-flavin reductase

# Drug_Target_3_Theoretical_pI:
7.76

# Drug_Target_3_Transmembrane_Regions:
None

#END_DRUGCARD DB00140
